APOE ε4 allele in Alzheimer's and non-Alzheimer's dementias
1996; Elsevier BV; Volume: 348; Issue: 9032 Linguagem: Inglês
10.1016/s0140-6736(05)65372-x
ISSN1474-547X
AutoresShigeru Itabashi, Hiroyuki Arai, Susumu Higuchi, Hidetada Sasaki, John Q. Trojanowski,
Tópico(s)Dementia and Cognitive Impairment Research
ResumoAccumulating evidence shows that the apolipoprotein E (APOE) ε4 allele is strongly associated with late-onset familial and sporadic Alzheimer's disease (AD) as a major susceptibility gene or risk factor that increases the incidence and lowers the age of onset of AD in a dose-dependent manner. 1 Corder EH Saunders AM Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-923 Crossref PubMed Scopus (7198) Google Scholar However, the diagnostic value of APOE genotyping remains enigmatic. Saunders and colleagues (July 13, p 90) 2 Saunders AM Hulette C Welsh-Bohmer KA et al. Specificity, sensitivity, and predictive value of apolipoprotein–E genotyping for sporadic Alzheimer's disease. Lancet. 1996; 348: 90-93 Summary Full Text Full Text PDF PubMed Scopus (215) Google Scholar report that the presence of the APOE ε4 allele in demented patients is highly specific and predictive for AD. To assist this issue further, we present data on APOE testing from demented patients with necropsy-confirmed diagnoses.
Referência(s)